Compare · GILD vs PDLI
GILD vs PDLI
Side-by-side comparison of Gilead Sciences Inc. (GILD) and PDL BioPharma, Inc. (PDLI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PDLI operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD carries a market cap of $160.15B.
- GILD has hit the wire 21 times in the past 4 weeks while PDLI has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for PDLI).
- Company
- Gilead Sciences Inc.
- PDL BioPharma, Inc.
- Price
- $129.01+1.15%
- -
- Market cap
- $160.15B
- -
- 1M return
- -2.80%
- -
- 1Y return
- +18.29%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 1992
- News (4w)
- 21
- 0
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- FDA Approval for BIKTARVY issued to GILEAD SCIENCES INC
- Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Latest PDLI
- Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting
- BiomX Announces the Appointment of Susan Blum to its Board of Directors
- Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer
- SEC Form SC TO-I/A filed
- SEC Form SC 13G/A filed
- SEC Form SC 13G/A filed
- SEC Form EFFECT filed
- SEC Form EFFECT filed
- SEC Form EFFECT filed
- SEC Form EFFECT filed